Gilead Sciences (NASDAQ:GILD) Price Target Raised to $95.00 at Robert W. Baird

Gilead Sciences (NASDAQ:GILD) had its target price boosted by Robert W. Baird from $80.00 to $95.00 in a research note published on Thursday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

Several other research firms have also weighed in on GILD. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $74.00 to $96.00 in a report on Monday, October 21st. Royal Bank of Canada lifted their target price on shares of Gilead Sciences from $75.00 to $81.00 and gave the company a “sector perform” rating in a report on Thursday. Finally, Barclays raised their price objective on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday. Eleven analysts have rated the stock with a hold rating, ten have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $91.50.

Gilead Sciences Price Performance

GILD opened at $96.57 on Thursday. The stock’s 50 day moving average price is $85.30 and its 200-day moving average price is $75.09. Gilead Sciences has a 52-week low of $62.07 and a 52-week high of $98.32. The stock has a market capitalization of $120.23 billion, a PE ratio of 1,073.00, a price-to-earnings-growth ratio of 3.36 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.11.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same period in the prior year, the business earned $2.29 EPS. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. On average, equities research analysts predict that Gilead Sciences will post 4.34 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.19%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 62,437 shares of company stock worth $5,374,825 in the last 90 days. 0.16% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Manning & Napier Advisors LLC acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth $25,328,000. Legal & General Group Plc boosted its holdings in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after acquiring an additional 93,068 shares in the last quarter. IRON Financial LLC purchased a new stake in shares of Gilead Sciences during the third quarter worth about $830,000. GSA Capital Partners LLP acquired a new position in shares of Gilead Sciences during the first quarter valued at about $462,000. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of Gilead Sciences by 13.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock valued at $19,630,000 after purchasing an additional 33,162 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.